Moderna In-Licenses Autolus' Technology For mRNA-Based Cancer Therapeutics

• Moderna Inc (NASDAQ: MRNA) has exercised its option to license Autolus Therapeutics plc's (NASDAQ: AUTL) proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics.

• This follows an original agreement with Moderna announced in August 2021, granting Moderna an exclusive option to license Autolus' proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics.

• Related: Moderna Shares Are Surging After Merck Exercised Personalized Cancer Vaccine Pact.

• On exercise of the option, Autolus has received an option exercise payment and is eligible to receive development and commercial milestone payments for each product successfully commercialized.

• In addition, Autolus would receive royalties on net sales of all products commercialized under the agreement.

• Price Action: AUTL shares are up 8.89% at $3.24 on the last check Wednesday.

See more from Benzinga

• Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System

• If You Invested $1,000 In The Dow Jones When Donald Trump Left White House, Here's How Much You'd Have No

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.